The LSD1/HDAC dual-target inhibitor for cancer therapy: Challenge and opportunity

Area of Science:

• Oncology
• Epigenetics
• Medicinal Chemistry

Background:

• Epigenetic regulators like lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) are crucial in cancer development.
• Overexpression of LSD1 and HDAC in tumors drives proliferation and differentiation via histone modification.
• Single-target inhibitors face challenges like compensatory signaling and drug resistance, limiting clinical efficacy.

Purpose of the Study:

• To review recent advancements in dual-target inhibitors for LSD1 and HDAC in cancer therapy.
• To highlight the potential of bifunctional inhibitors in overcoming limitations of single-target agents.
• To stimulate future research and structural optimization of these novel therapeutic agents.

Main Methods:

• Literature review focusing on preclinical and clinical studies of LSD1/HDAC dual-target inhibitors.
• Analysis of reported dual-target inhibitors for their efficacy, selectivity, and toxicity profiles.
• Examination of the mechanisms underlying the synergistic anti-tumor effects of these compounds.

Main Results:

• Bifunctional inhibitors targeting both LSD1 and HDAC demonstrate synergistic chromatin remodeling and enhanced anti-tumor effects.
• Several dual-target inhibitors have shown potent tumor suppression with favorable toxicity and selectivity profiles.
• These inhibitors represent a promising strategy to overcome drug resistance and compensatory signaling pathways.

Conclusions:

• Dual-target LSD1/HDAC inhibitors offer a novel and promising direction for cancer therapy.
• Further research is needed to optimize pharmacokinetics, enhance target selectivity, and understand resistance mechanisms.
• Systematic validation is crucial for the successful clinical translation of these advanced therapeutic agents.